HK1244680A1 - 用於靜脈內施用反丁烯二酸酯以治療神經疾病的方法和組合物 - Google Patents
用於靜脈內施用反丁烯二酸酯以治療神經疾病的方法和組合物Info
- Publication number
- HK1244680A1 HK1244680A1 HK18104073.2A HK18104073A HK1244680A1 HK 1244680 A1 HK1244680 A1 HK 1244680A1 HK 18104073 A HK18104073 A HK 18104073A HK 1244680 A1 HK1244680 A1 HK 1244680A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fumarates
- compositions
- treatment
- methods
- intravenous administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562136431P | 2015-03-20 | 2015-03-20 | |
PCT/US2016/023021 WO2016153957A2 (en) | 2015-03-20 | 2016-03-18 | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1244680A1 true HK1244680A1 (zh) | 2018-08-17 |
Family
ID=55702079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18104073.2A HK1244680A1 (zh) | 2015-03-20 | 2018-03-23 | 用於靜脈內施用反丁烯二酸酯以治療神經疾病的方法和組合物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20180289655A1 (zh) |
EP (1) | EP3270895A2 (zh) |
JP (1) | JP2018508559A (zh) |
KR (1) | KR20170138437A (zh) |
CN (1) | CN107666905A (zh) |
AR (1) | AR104029A1 (zh) |
AU (1) | AU2016235743A1 (zh) |
CA (1) | CA2979544A1 (zh) |
EA (1) | EA201792076A1 (zh) |
HK (1) | HK1244680A1 (zh) |
IL (1) | IL254576A0 (zh) |
MA (1) | MA41785A (zh) |
MX (1) | MX2017012239A (zh) |
TW (1) | TW201642847A (zh) |
WO (1) | WO2016153957A2 (zh) |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
ES2297461T3 (es) * | 2003-09-09 | 2008-05-01 | Fumapharm Ag | Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma. |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
ES2523796T1 (es) * | 2004-10-08 | 2014-12-01 | Forward Pharma A/S | Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico |
EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
EP2139467B1 (en) * | 2007-02-08 | 2016-09-21 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
US20110112196A1 (en) * | 2007-02-08 | 2011-05-12 | Matvey E Lukashev | Nrf2 screening assays and related methods and compositions |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
ES2477884T3 (es) | 2008-08-19 | 2014-07-18 | Xenoport, Inc. | Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso |
JP2012525385A (ja) | 2009-04-29 | 2012-10-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 神経変性および神経炎症の治療 |
ME02317B (me) | 2010-02-12 | 2016-06-20 | Biogen Ma Inc | Neuroprotekcija kod demijelinizacijskih bolesti |
JP5072128B2 (ja) * | 2011-03-31 | 2012-11-14 | 株式会社ワコール | カップ部を有する衣類 |
WO2013022882A1 (en) | 2011-08-08 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Combination therapy for treatment of inflammatory demyelinating disease |
US9421273B2 (en) * | 2011-12-16 | 2016-08-23 | Biogen Ma Inc. | Silicon-containing fumaric acid esters |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
SG11201404705YA (en) | 2012-02-07 | 2014-10-30 | Biogen Idec Inc | Pharmaceutical compositions containing dimethyl fumarate |
US20140057918A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
WO2014096425A2 (en) | 2012-12-21 | 2014-06-26 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
ES2733961T3 (es) | 2012-12-21 | 2019-12-03 | Biogen Ma Inc | Derivados de fumarato sustituidos con deuterio |
CN105163730B (zh) | 2013-01-08 | 2018-10-30 | 帕萨罗杰卡有限公司 | 用于治疗脱髓鞘疾病的方法和组合物 |
WO2014138298A1 (en) | 2013-03-05 | 2014-09-12 | University Of Chicago | Treatment of demyelinating disorders |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US20150079180A1 (en) * | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
WO2016074684A1 (en) * | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
-
2016
- 2016-03-17 MA MA041785A patent/MA41785A/fr unknown
- 2016-03-18 KR KR1020177029928A patent/KR20170138437A/ko not_active IP Right Cessation
- 2016-03-18 AR ARP160100749A patent/AR104029A1/es unknown
- 2016-03-18 CN CN201680028617.1A patent/CN107666905A/zh not_active Withdrawn
- 2016-03-18 MX MX2017012239A patent/MX2017012239A/es unknown
- 2016-03-18 AU AU2016235743A patent/AU2016235743A1/en not_active Withdrawn
- 2016-03-18 WO PCT/US2016/023021 patent/WO2016153957A2/en active Application Filing
- 2016-03-18 TW TW105108578A patent/TW201642847A/zh unknown
- 2016-03-18 EP EP16715662.9A patent/EP3270895A2/en not_active Withdrawn
- 2016-03-18 CA CA2979544A patent/CA2979544A1/en not_active Abandoned
- 2016-03-18 EA EA201792076A patent/EA201792076A1/ru unknown
- 2016-03-18 JP JP2017549232A patent/JP2018508559A/ja not_active Withdrawn
- 2016-03-18 US US15/559,265 patent/US20180289655A1/en not_active Abandoned
-
2017
- 2017-09-18 IL IL254576A patent/IL254576A0/en unknown
-
2018
- 2018-03-23 HK HK18104073.2A patent/HK1244680A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018508559A (ja) | 2018-03-29 |
AR104029A1 (es) | 2017-06-21 |
AU2016235743A1 (en) | 2017-10-12 |
WO2016153957A3 (en) | 2016-11-10 |
TW201642847A (zh) | 2016-12-16 |
EA201792076A1 (ru) | 2018-04-30 |
US20180289655A1 (en) | 2018-10-11 |
MX2017012239A (es) | 2018-06-27 |
WO2016153957A2 (en) | 2016-09-29 |
CN107666905A (zh) | 2018-02-06 |
MA41785A (fr) | 2018-01-23 |
KR20170138437A (ko) | 2017-12-15 |
IL254576A0 (en) | 2017-11-30 |
EP3270895A2 (en) | 2018-01-24 |
CA2979544A1 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
HRP20190117T1 (hr) | iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA | |
IL298690B1 (en) | Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions | |
EP3349783C0 (en) | COMPOSITIONS AND METHODS ASSOCIATED WITH THE TREATMENT OF DISEASES | |
IL274702A (en) | Compounds and Methods for Neurological Diseases | |
HK1256721A1 (zh) | 用於治療眼部病症的化合物和組合物 | |
EP3268007A4 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
IL249439A0 (en) | A compound and method for the treatment of neurological diseases and brain injury | |
ZA201903003B (en) | Treatment of neurological diseases | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
IL264070A (en) | Methods and preparations for the treatment of disorders and diseases involving rdh12 | |
GB201412578D0 (en) | Treatment of neurological diseases | |
EP3362085C0 (en) | COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH MUCIN | |
IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
HK1244680A1 (zh) | 用於靜脈內施用反丁烯二酸酯以治療神經疾病的方法和組合物 | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
IL254140A0 (en) | Preparations and combinations for use in the treatment of angiogenic diseases and disorders | |
EP3247396A4 (en) | Methods and compositions for the treatment of diseases and disorders | |
SG11201706952VA (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases |